自从发现Wnt-β-catenin通路中的突变致使一些人类癌症，人们便致力于开发阻止其活性的治疗方式。尽管已经做了许多努力，但目前还没有能直接抑制Wnt信号传导的药物可供临床使用。相反，利用新分子模拟Wnt蛋白的活性以特定的方式激活Wnt通路也成为可能，从而为控制组织干细胞活动和治疗各种退行性疾病提供了新的可能性。我们描述了调节Wnt-β-catenin通路的抗体疗法，以及在肿瘤和再生医学药物开发中的进展和挑战。版权所有 © 2023 Elsevier Ltd.

Since the recognition that mutations in components of the Wnt-β-catenin pathway underlie some human cancers, considerable attention has been dedicated to developing therapeutic modalities to block its activity. Despite numerous efforts, no drug directly inhibiting Wnt signaling is currently clinically available. Conversely, activating the Wnt pathway in a specific manner has recently been made possible with new molecules mimicking the activity of Wnt proteins, thus offering new possibilities for controlling tissue stem cell activity and for the rational treatment of various degenerative conditions. We describe the landscape of antibody modalities that modulate the Wnt-β-catenin pathway, and detail the advances and challenges in both cancer and regenerative medicine drug development.Copyright © 2023 Elsevier Ltd. All rights reserved.